Italian, wow, not Bracco, scooped up the rest of EU, Russia, Turkey etc.. about $4M in upfront, Recordati has agreed to obtain all necessary regulatory approvals at its sole cost.
nothing on Latin America yet,
Established in 1926, Recordati is an international pharmaceutical group, listed on the Italian Stock Exchange (Bloomberg REC IM), with a total staff of around 4,000, dedicated to the research, development, manufacturing and marketing of pharmaceuticals. Recordati is headquartered in Milan, Italy, with operations in the main European countries, in Russia, in other Central and Eastern European countries, in Turkey, in the United States of America and in North Africa. An efficient field force of medical representatives promotes a wide range of innovative pharmaceuticals, both proprietary and under license, in a number of therapeutic areas including a specialized business dedicated to treatments for rare diseases. Recordati is a partner of choice for new product licenses for its territories. Recordati is committed to the research and development of new drug entities within the cardiovascular and urogenital therapeutic areas and of treatments for rare diseases.
For further information, please visit the Recordati website: www.recordati.com.
News 
Market Data 
Discover 
AI
